The global market for primary sclerosing cholangitis (PSC) is poised for remarkable expansion, with projections indicating a valuation of USD 314.26 million by 2033. This robust growth, driven by a notable compound annual growth rate (CAGR) of 7.6% from 2023 to 2033, highlights the increasing focus on addressing liver diseases and the rising trend of …